Evaluates new treatments for hyperphosphatemia in chronic kidney disease, suggesting improved management options.
Hyperphosphatemia is a common metabolic disturbance in chronic kidney disease (CKD), affecting 5-15% of patients in early stages and >80% of those on dialysis[1]. Progressive decline in kidney f...
No takes yet. Share an insight, caveat, or question.
Magagnoli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: